Core Insights - Olo Inc. (OLO) shows potential as a strong investment due to significant revisions in earnings estimates, indicating an improving earnings outlook [1][9] - Analysts are increasingly optimistic about Olo's earnings prospects, which is expected to positively influence its stock price [2][3] - The Zacks Rank system, which rates stocks from 1 (Strong Buy) to 5 (Strong Sell), has a proven track record, with 1 ranked stocks averaging a +25% annual return since 2008 [3][8] Current-Quarter Estimate Revisions - For the current quarter, Olo is projected to earn $0.08 per share, reflecting a +60% increase from the same quarter last year [5] - In the last 30 days, two estimates for Olo have been revised upward while one has been revised downward, leading to a 150% increase in the Zacks Consensus Estimate [5] Current-Year Estimate Revisions - The full-year earnings estimate for Olo is $0.31 per share, representing a +40.91% change from the previous year [6] - Over the past month, one estimate has been revised upward with no negative revisions, resulting in a 92.86% increase in the consensus estimate [7] Favorable Zacks Rank - Olo currently holds a Zacks Rank 2 (Buy) due to positive estimate revisions, which suggests strong potential for stock performance [8] - Research indicates that stocks with Zacks Rank 1 and 2 significantly outperform the S&P 500 [8] Bottom Line - Olo's stock has gained 51.2% over the past four weeks, driven by solid estimate revisions, making it a candidate for portfolio addition [9]

Core Viewpoint - Edgewise Therapeutics, Inc. (EWTX) has received a Zacks Rank 2 (Buy) upgrade due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily based on a company's changing earnings picture, specifically tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Edgewise Therapeutics reflects a positive outlook on its earnings, which could positively affect its stock price [4][6]. Impact of Earnings Estimates on Stock Prices - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, influencing their buying or selling actions, which subsequently affects stock prices [5]. Recent Performance of Edgewise Therapeutics - Edgewise Therapeutics is projected to earn -$1.82 per share for the fiscal year ending December 2025, indicating a year-over-year decline of 25.5% [9]. - Over the past three months, the Zacks Consensus Estimate for Edgewise Therapeutics has increased by 2.1%, suggesting a positive trend in earnings estimates [9]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of Edgewise Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11].

Legacy Education Inc. (LGCY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...

Shares of Rambus (RMBS) have gained 23.3% over the past four weeks to close the last trading session at $56.35, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $72.25 indicates a potential upside of 28.2%.The mean estimate comprises eight short-term price targets with a standard deviation of $9.97. While the lowest estimate of $55 indicates a 2.4% decline from the current price ...

Shares of CI&T Inc. (CINT) have gained 21.5% over the past four weeks to close the last trading session at $6.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $8.23 indicates a potential upside of 34.9%.The mean estimate comprises eight short-term price targets with a standard deviation of $1.33. While the lowest estimate of $6.50 indicates a 6.6% increase from the current pr ...

Shares of West Pharmaceutical Services (WST) have gained 7.3% over the past four weeks to close the last trading session at $216.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $284 indicates a potential upside of 31.1%.The average comprises 10 short-term price targets ranging from a low of $245 to a high of $355, with a standard deviation of $34.94. While the lowest estimat ...

Group 1 - HNI closed at $47.92, with a 16.3% gain over the past four weeks, and analysts set a mean price target of $66, indicating a 37.7% upside potential [1] - The average price targets range from a low of $63 to a high of $70, with a standard deviation of $3.61, suggesting a 31.5% to 46.1% upside from the current price [2] - Analysts show strong agreement on HNI's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for HNI has increased by 7.1% over the last 30 days, with one estimate moving higher and no negative revisions [12] - HNI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be a good guide for potential upside [13]

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about NextEra Energy (NEE) .NextEra currently has an average brokerage recommendation (ABR) of 1.91, ...

Backblaze, Inc. (BLZE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual inv ...

Core Viewpoint - Gogo (GOGO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, particularly influenced by institutional investors [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional buying or selling, which affects stock prices [4]. Gogo's Earnings Outlook - Gogo is projected to earn $0.44 per share for the fiscal year ending December 2025, reflecting a year-over-year decline of 2.2% [8]. - Over the past three months, the Zacks Consensus Estimate for Gogo has increased by 5.6%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Gogo's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].